Moreover, clinical studies evidence that high levels of PR correlate with decreased metastatic events in early stage disease [17], while ER-positive/PR-negative breast carcinomas are associated with worse long-term outcomes and metastases after neoadjuvant therapy [18]. This evidence concerns the gene ESR1 and breast carcinoma.